CRP, TNF-Alpha and IL-1 Beta Fell Against Placebo

In the Moscow trial, interleukin-1 beta (IL-1 beta), tumour necrosis factor alpha (TNF-alpha) and C-reactive protein (CRP) fell against placebo, while interleukin-6 (IL-6) and interleukin-10 (IL-10) did not. Weight and waist circumference fell in the same trial, so that evidence cannot separate the hormone from the fat loss, and no trial has shown the marker change alters health outcomes. At Longevity Benchmark, we read trial evidence to separate marker changes driven by hormone therapy from changes caused by weight loss. That study was a 184-man randomised, placebo-controlled trial of men with both metabolic syndrome and hypogonadism, published by Kalinchenko and colleagues in Clinical Endocrinology. Of those men, 113 received testosterone replacement therapy (TRT) and 71 received placebo.

The investigators tracked five inflammatory markers across the 30-week intervention. A patient looking at the full inflammation marker inventory will notice that these circulating proteins do not behave as a single entity.

The Verdict

Testosterone undecanoate injections reduced CRP, TNF-alpha, and IL-1 beta in hypogonadal men with metabolic syndrome over 30 weeks. Because treated men also lost significant body weight and waist circumference, the trial design cannot prove whether testosterone lowered the cytokines directly or whether fat loss drove the improvement. IL-6 did not shift, and no trial proves that these marker drops prevent cardiovascular events.

What the Trial Randomised

The Moscow study enrolled 184 men between the ages of 35 and 70 years who met strict diagnostic criteria. Every participant presented with both confirmed metabolic syndrome and laboratory-verified hypogonadism. Investigators randomised 113 men to receive intramuscular testosterone undecanoate at a dose of 1000 mg. The remaining 71 men were randomised to receive an identical intramuscular placebo injection.

Dosing took place at baseline, at week 6, and at week 18, following the standard clinical loading schedule for testosterone undecanoate. The total observation window lasted 30 weeks. Study retention was high across both arms of the trial. A total of 92.9% of participants in the testosterone arm completed the full 30-week protocol. In the placebo group, 91.5% of men finished the trial.

The Confound the Design Could Not Remove

Body weight, body mass index (BMI), and waist circumference all dropped significantly in the testosterone arm compared to the placebo group. Circulating fasting insulin and leptin levels fell significantly as well. In contrast, fasting blood glucose and the overall blood lipid profile did not change significantly over the 30-week period. These physical changes create an unavoidable biological confound when interpreting the inflammatory blood markers.

Visceral adipose tissue functions as an active endocrine organ that directly secretes inflammatory cytokines. Visceral fat is itself a source of IL-6 and CRP. When a patient loses abdominal fat and waist circumference, systemic inflammatory markers decline naturally as a consequence of reduced adipose volume. Because both testosterone concentrations and body composition shifted at the exact same time, the trial cannot isolate the causal driver.

The data do not show whether testosterone molecules directly inhibited cytokine expression in immune cells or whether the reduction in visceral fat lowered cytokine output. A man who loses visceral fat will usually see an inflammation panel read as less inflamed. The hormone cannot take the credit on its own. The fat loss and the hormone replacement occurred together, leaving the direct mechanism unverified.

Correlation Is Not the Same Question

The association evidence is a weak inverse correlation between total testosterone and high-sensitivity C-reactive protein (hs-CRP). We set out its limits in the cross-sectional testosterone and hs-CRP correlations, where the cohorts are cross-sectional and the authors state that neither study establishes causality. An observational association is no evidence that prescribed testosterone reverses systemic inflammation.

Cross-sectional studies take one snapshot. In these cohorts, obesity, poor metabolic health, chronic illness, and physical inactivity independently depress testosterone production while elevating inflammatory markers. Causation can also run the other way, which a cross-sectional design cannot settle. The observed correlation often reflects underlying poor metabolic health rather than a direct protective effect of the hormone.

Randomised controlled trials ask a fundamentally different question than observational surveys. A trial tests whether intervening on hormone levels produces an intentional, downstream change in biological markers or clinical endpoints. A population association does not predict what one man gets from treatment. Only prospective interventional trials with matched control groups can determine whether restoring androgen concentrations alters cytokine activity.

A Lower Marker Is Not a Health Outcome

A measurable decrease in a circulating inflammatory protein does not prove that a patient will experience fewer clinical health problems. A biomarker shift does not always translate into tangible clinical improvements such as longer life or fewer cardiovascular events. When clinicians assess lab work, reading a high CRP result requires looking beyond single-organ explanations because acute infections, tissue trauma, and rheumatic conditions move the marker dramatically. No clinical trial has demonstrated that lowering CRP through testosterone administration reduces heart attacks, strokes, or cardiovascular mortality.

The clinical outcome question was evaluated on a large scale by Lincoff and colleagues in the TRAVERSE trial, published in the New England Journal of Medicine. The TRAVERSE trial randomised 5,246 men aged 45 to 80 years with preexisting cardiovascular disease or elevated cardiovascular risk and confirmed hypogonadism to transdermal testosterone gel or placebo. The trial demonstrated cardiovascular noninferiority for major adverse cardiac events, recording primary endpoint events in 7.0% of the testosterone group and 7.3% of the placebo group. Testosterone did not reduce cardiovascular events or provide superior cardiovascular protection compared to placebo.

Furthermore, the TRAVERSE study documented specific adverse safety signals in the testosterone arm. Treated patients experienced higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury compared to the placebo cohort. If the reductions in CRP and cytokines observed in smaller trials provided systemic vascular protection, that benefit did not reduce cardiovascular events in high-risk patients. Surrogate blood markers cannot substitute for hard clinical endpoints when evaluating the actual health impact of hormone therapy.

Inflammation Against Swelling

Patients and searchers frequently conflate systemic biochemical inflammation with physical swelling and fluid accumulation. Men starting TRT report tight rings, puffy ankles or aching knees. They conclude the hormone is inflaming their joints. Acute puffiness on testosterone typically comes from water and sodium retention rather than from cytokine-mediated joint pathology. We examine the mechanism in fluid retention on TRT, where a rat study showed testosterone stimulating renal sodium channels through the androgen receptor.

True inflammation involves an organised immune response mediated by cellular signalling molecules like cytokines, chemokines, and acute-phase reactants. Peripheral fluid retention involves hydrostatic shifts in the vascular space that force fluid into interstitial tissues without activating inflammatory cascades. In the Moscow trial no inflammatory marker rose on treatment, even though fluid shifts in clinical practice can mimic the physical sensation of joint congestion.

Inflammatory Marker Changes in the Moscow Trial Over 30 Weeks
Inflammatory MarkerDirection of ChangeStatistical Significance
C-reactive protein (CRP) Decreased Statistically significant
Tumour necrosis factor alpha (TNF-alpha) Decreased Statistically significant
Interleukin-1 beta (IL-1 beta) Decreased Statistically significant
Interleukin-6 (IL-6) No significant change Not significant
Interleukin-10 (IL-10) No significant change Not significant

A therapy that moves three of five cytokines is not a universal anti-inflammatory.

Who This Answer Is Not For

None of this applies to a man whose testosterone is normal. Administering exogenous testosterone to a man whose hormone levels already sit within the healthy reference range does not replicate the metabolic findings of hypogonadal trials, and no trial here tested it. A man with normal testosterone who finds an elevated hs-CRP on a routine panel has a question for a physician, who can look at what else raises the marker.

This evidence also does not apply to men experiencing joint pain without a documented clinical hormone deficiency. Assuming that joint stiffness or connective tissue discomfort stems from low testosterone leads patients to overlook genuine orthopaedic, rheumatological, or mechanical injuries. Joint pain without a diagnosed deficiency is a question for a clinician. Similarly, the trial results cannot be generalised to individuals without metabolic syndrome, or to different testosterone esters, transdermal gels, or subcutaneous pellet formulations.

Our Takeaway

In men who had both metabolic syndrome and a measured low testosterone, CRP, TNF-alpha, and IL-1 beta fell against placebo in the Moscow trial and IL-6 did not. Because weight, BMI, and waist circumference fell in the same trial, that is not evidence the hormone moved the markers on its own, and no trial has shown the marker change alters health. The findings apply specifically to hypogonadal men with metabolic syndrome over a 30-week treatment duration on injected testosterone undecanoate. Nothing in this research was measured in men with normal baseline testosterone, in men without metabolic syndrome, or over periods longer than 30 weeks.

What would change our answer is a prospective randomised trial in hypogonadal men that holds body weight and waist circumference completely constant while demonstrating significant cytokine reductions. Such a trial would cleanly separate the hormonal effect from the metabolic benefits of losing visceral fat. Alternatively, a large interventional trial powered to detect clinical endpoints that shows improved cardiovascular outcomes directly mediated by cytokine changes would establish practical clinical relevance. If you are reviewing a raised inflammatory marker on testosterone therapy, schedule an appointment with your prescribing clinician and ask what else could be raising it.

Frequently Asked Questions

Does TRT help with inflammation?

Testosterone replacement therapy (TRT) lowered three inflammatory markers in one randomised trial, but the evidence cannot prove the hormone acted on its own. In that study, C-reactive protein (CRP), tumour necrosis factor alpha (TNF-alpha), and interleukin-1 beta (IL-1 beta) fell over 30 weeks. However, participants also lost weight and waist circumference during treatment. Because visceral fat generates inflammatory signals, the marker reductions may have come from fat loss rather than testosterone itself. Furthermore, two other markers showed no significant shift, and no trial has proved that lowering these markers improves clinical health.

Is testosterone anti-inflammatory?

Testosterone is described as anti-inflammatory because circulating levels correlate inversely with high-sensitivity C-reactive protein in two cross-sectional cohorts. In addition, one placebo-controlled trial found decreases in three of the five cytokines it measured. Even so, the biological picture remains mixed. In that same trial, interleukin-6 (IL-6) and interleukin-10 (IL-10) did not change significantly. Whether the hormone suppresses cytokine production directly in human tissue or acts by reducing visceral fat mass remains unproven.

Does TRT lower CRP?

Testosterone replacement therapy lowered C-reactive protein (CRP) in men who had both hypogonadism and metabolic syndrome in the Moscow trial. Treated men received injections of testosterone undecanoate over 30 weeks and registered a significant drop in CRP compared to placebo. However, that trial also recorded significant weight loss and waist reduction in the treated group. Because fat loss lowers CRP by itself, researchers cannot determine how much of the reduction was caused directly by the hormone.

Can TRT cause inflammation or joint pain?

The Moscow trial did not measure joint damage. Testosterone product labelling and our fluid-retention analysis both describe sodium and water retention, which can cause swelling in the ankles, feet and hands. Men often read that periarticular stiffness as joint inflammation. In the Moscow trial no inflammatory marker rose on treatment.

Did IL-6 change on testosterone in the trial?

Interleukin-6 (IL-6) did not change significantly on testosterone undecanoate in the Moscow trial. While CRP, TNF-alpha, and IL-1 beta decreased against placebo, circulating levels of IL-6 and IL-10 remained statistically flat over the 30-week treatment period. This selective marker response shows that testosterone therapy does not produce a uniform reduction across all inflammatory cytokines.

Does a lower CRP on TRT mean better health outcomes?

A lower C-reactive protein level on testosterone therapy does not automatically indicate better health outcomes. No clinical trial has tested whether bringing down CRP with testosterone reduces heart attacks, strokes, or overall mortality. The TRAVERSE trial followed 5,246 men to evaluate cardiovascular events. It found noninferiority for major adverse cardiac events alongside higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury, where marker changes do not guarantee clinical protection.